Figure 1
STI571-induced apoptosis with TF-1 BCR-ABL cells and blast cells from primary Ph-positive ALL or CML-blastic crisis patients. (a) Inhibition of BCR-ABL tyrosine phosphorylation by STI571. TF-1 BCR-ABL cells were incubated with 1 M of STI571 for the indicated time, and cell lysates were then immunoprecipitated with anti-ABL antibody. These immune complexes were immunoblotted with antiphosphotyrosine mAb (4G10). (b) Cells were cultured with the indicated reagents for 48 h, and then stained with FITC-conjugated APO2.7 mAb prior to analysis by flow cytometry. Each number represents the percentage of APO2.7 mAb-positive cells detected. (c) Primary blast cells were cultured at a high density (1 × 10 6 cells/ml) with or without STI571 for 48 h, then stained with FITC-conjugated APO2.7 mAb, and analysed by flow cytometry. Each number represents the percentage of APO2.7 mAb-positive cells.
TO THE EDITOR
BCR-ABL is a chimeric oncoprotein that exhibits deregulated tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome (Ph)-positive leukemia.
1 BCR-ABL has been found in most patients with chronic myelogenous leukemia (CML) and in about 30% of adult patients with acute lymphoblastic leukemia (ALL). Targeting the tyrosine kinase activity of BCR-ABL may be a feasible strategy towards improved therapy for Ph-positive leukemia.
2 The 2-phenylaminopyrimidine derivative STI571 is a recently designed tyrosine kinase inhibitor that competitively inhibits ATP binding in the kinase Correspondence: A Nakajima; Fax: 813 5381 6651
Leukemia domains of both c-ABL and BCR-ABL.
3 STI571 is specifically active both in vitro and in vivo against a variety of BCR-ABL transformed cells. 3, 4 The combinations of STI571 with cytarabine or etoposide showed synergistic activities in BCR-ABL transformed cells.
5 STI571 may give hope for a better control of CML. 6 In the present study, we investigated whether STI571 acts in vitro against Ph-positive ALL or CML-blastic crisis (CML-BC) cells, both of which give rise to aggressive diseases with poor prognosis. First, we examined the association of STI571-induced apoptosis with the inhibition of BCR-ABL tyrosine kinase autophosphorylation (Figure 1a , b). STI571 was kindly provided by Novartis (Basel, Switzerland). Inhibition of p210 BCR-ABL tyrosine phosphorylation was clearly demonstrated by immunoprecipitation with anti-ABL antibody followed by anti-phosphotyrosine immunoblotting using TF-1 BCR-ABL cells engi- neered to express p210 BCR-ABL (Figure 1a) . The incidence of apoptosis was determined by flow cytometric analysis with an FITCconjugated APO2.7 monoclonal antibody (clone 2.7), which was raised against the 38 kDa mitochondrial membrane protein (7A6 antigen) expressed by cells undergoing apoptosis. 7 Incubation with up to 10 M STI571 for 48 h did not result in increased apoptosis among parental TF-1 cells in the presence of GM-CSF (100 U/ml). Further, even though the incubation of TF-1 BCR-ABL cells with STI571 at a concentration of either 1 M or 10 M induced apoptosis in the absence of GM-CSF, the addition of GM-CSF abated the apoptotic effects of STI571 in these cells (Figure 1b) .
Leukemia
Next, we examined the induction of apoptosis in primary leukemic blasts from 10 patients with acute leukemia (Figure 1c) (Table 1 ). All patients provided informed consent prior to conducting studies. Leukemic blasts were isolated from bone marrow of four patients with Ph-positive ALL (p185 BCR-ABL) (from cases 1, 2, 3 and 4), two patients with Ph-negative ALL (cases 5 and 6) and four patients with CML-myeloid BC (p210 BCR-ABL) (from cases 7, 8, 9 and 10) ( Table  1) . Blast cells were incubated in suspension cultures in the presence of 1 or 10 M of STI571 for 48 h, and the occurrence of apoptosis was examined by flow cytometric analysis with FITC-conjugated APO2.7 monoclonal antibody (Figure 1c) . At a concentration of 1 M, STI571 induced apoptosis at very high frequencies in the blast cells from all patients with Ph-positive ALL, whereas no increased apoptosis against background levels was seen in the blast cells from two patients with Ph-negative ALL even in the presence of 10 M STI571 (Figure 1c and Table 1 ). STI571 also induced apoptosis in blast cells from two of the four patients with CML-myeloid BC (cases 9 and 10), however, primary blast cells from CML-myeloid BC seem to be less sensitive to STI571 (Figure 1c and Table 1 ). Blast crisis is associated with genetic instability and complex karyotypes leading to the activation of other oncogenes in addition to BCR-ABL, as well as to the inactivation of tumor suppressor genes. It is not known if these additional abnormalities replace the requirement of the leukemic clone on BCR-ABL tyrosine kinase activity for survival in blast crisis, however, our results demonstrate that STI571 exhibits specific activity in Ph-positive ALL and some cases of CML-BC in vitro. Given the extremely poor prognosis of patients with Ph-positive ALL or CML-BC, the results described herein may provide a basis for attractive therapeutic strategies in treating these diseases.
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First Another molecular abnormality frequently found in MDS is the ectopic expression of the ecotropic virus integration site-1 (EVI-1) gene. The EVI-1 gene was cloned as a gene activated by viral integration in murine leukemia cells, and the human gene was located on the long arm of the chromosome 3 (3q26). The EVI-1 gene is scarcely expressed in normal human hematopoietic cells, but expression was found in some acute myeloblastic leukemia (AML) and MDS, with and without 3q26 abnormalities. 2 Kurokawa et al 3 reported that the EVI-1 protein interacts with SMAD3 protein and blocks the signal from TGF-␤, and in reporter assay overexpression of the EVI-1 protein suppresses transcriptional activation of the p15 gene promoter by TGF-
